Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 18/20 | 0.64 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TPH1 | P17752 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12498477 | 0.85 | PIK3CA (0.68) | PIK3CAPIK3R1MTORKMT2ATPH1 | |
| SCHEMBL12498959 | 0.84 | PIK3CA (0.69) | PIK3CAPIK3R1MTORKMT2ATPH1 | |
| SCHEMBL12498761 | 0.83 | PIK3CA (0.67) | PIK3CAPIK3R1MTORKMT2A | |
| SCHEMBL12499185 | 0.80 | PIK3CA (0.68) | PIK3CAPIK3R1MTORKMT2ATPH1 | |
| SCHEMBL12498708 | 0.78 | PIK3CA (1.00) | PIK3CAPIK3R1MTORKMT2ATPH1 | |
| SCHEMBL15379154 | 0.77 | PIK3CA (0.69) | PIK3CAPIK3R1MTORKMT2A | |
| SCHEMBL1311223 | 0.76 | PIK3CA (0.77) | PIK3CAMTORKMT2ATPH1 | |
| SCHEMBL15378718 | 0.76 | PIK3CA (1.00) | PIK3CAPIK3R1MTORKMT2A | |
| SCHEMBL12499847 | 0.76 | PIK3CA (1.00) | PIK3CAPIK3R1MTORKMT2ATPH1 | |
| SCHEMBL15378717 | 0.75 | PIK3CA (1.00) | PIK3CAPIK3R1MTORKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9481670-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2016-11-01 | — | — | US | claimed |
| US-20130303516-A1 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PTE. LTD. (SG) | 2013-11-14 | — | — | US | claimed |
| WO-2012101654-A2 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PVT. LTD (IN) | 2012-08-02 | — | — | WO | claimed |
| US-9481670-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2016-11-01 | — | — | US | disclosed |
| US-9481670-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2016-11-01 | — | — | US | disclosed |
| US-9481670-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2016-11-01 | — | — | US | disclosed |
| US-20130303516-A1 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PTE. LTD. (SG) | 2013-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303516-A1 | NOVEL TRIAZINE COMPOUNDS | MTOR, MAPKAP1, PIK3R5 | PIK3CA 13/4885PIK3R1 4/4885MTOR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.